In 2024, the FDA granted accelerated approval to repotrectinib as the third pan-tumor approval for the treatment of adult and pediatric patients (12 years or older) with unresectable solid tumors harboring an NTRK gene fusion with locally advanced or metastatic disease after treatment progression or those with no satisfactory alternative therapy options, based on efficacy data from the phase 1/2 TRIDENT-1 trial in TRK inhibitor naïve patients and those who previously received a TRK inhibitor (Solomon et al., 2023). This evidence concerns the gene NTRK1 and neoplasm.